Were the BDNF studies done in humans?

No. The neurotrophin expression work is rodent, principally rat hippocampus and frontal cortex.

Does Semax raise cortisol like ACTH?

No. The Pro-Gly-Pro substitution removes the steroidogenic activity of the parent hormone.

Semax (ACTH Fragment Peptide)

Semax Mechanism: Neurotrophin Expression

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

The principal reported mechanism is upregulation of neurotrophin gene expression. Rodent studies have reported increased BDNF and NGF expression in hippocampus and frontal cortex, with downstream signalling through the TrkB and TrkA receptors. Additional reported activity includes dopaminergic and serotonergic modulation.

Key facts

Primary reported targets: BDNF, NGF
Downstream receptors: TrkB (BDNF), TrkA (NGF)
Regions studied: Hippocampus, frontal cortex
Model organism: Rat
Key reference: Brain Res 2006 (PMID 16996037)
Also reported: Dopaminergic, serotonergic modulation
Steroidogenic activity: None — unlike parent ACTH

What neurotrophins are

Brain-derived neurotrophic factor and nerve growth factor are growth factors that support neuronal survival, differentiation and synaptic plasticity. BDNF signals through the TrkB receptor, NGF through TrkA. Both are involved in activity-dependent plasticity, which is why expression changes in these genes attract attention in cognitive and neuroprotection research.

What the studies actually measured

The 2003 Doklady Biological Sciences paper reported that Semax stimulates BDNF expression across regions of the rat brain in vivo. The 2006 Brain Research study reported regulation of both BDNF and trkB expression in the rat hippocampus. A 2010 Journal of Molecular Neuroscience paper compared the temporal dynamics of NGF and BDNF gene expression across hippocampus and frontal cortex. These are gene- and protein-expression measurements in rodents, not behavioural or clinical endpoints.

Research material referenced

Semax 10mg — third-party HPLC tested

View — £24.99

Expression is upstream of effect

This distinction is worth holding onto. Demonstrating that a compound raises BDNF messenger RNA in rat hippocampus establishes that it does something measurable to that pathway. It does not by itself establish a functional consequence, and it certainly does not establish one in a different species. The gap between an expression change and an outcome is where a great deal of peptide literature quietly overreaches.

The wider transcriptional picture

A 2014 BMC Genomics study took a broader approach, reporting that Semax affects expression of genes related to the immune and vascular systems in a rat model of focal cerebral ischaemia. That is a considerably wider signature than neurotrophins alone, and it suggests the compound's transcriptional effects are not confined to a single pathway.

What separates it from ACTH

The parent hormone acts on melanocortin receptors and stimulates adrenal steroidogenesis. Semax does not, because the residues responsible were replaced by Pro-Gly-Pro. Whatever central activity the peptide has is therefore not secondary to a corticosteroid response, which is the main confound the design was intended to eliminate.

What remains unresolved

No receptor has been definitively established as the primary target. The mechanistic literature describes downstream consequences — expression changes, neurotransmitter modulation — more confidently than it describes the initiating molecular event. That is a genuine gap, not a summary omission.

Extended research context

The Semax (ACTH Fragment Peptide) deep dive

Deep dive: what the Pro-Gly-Pro extension actually accomplishes

Semax is built from a four-residue fragment of ACTH with Pro-Gly-Pro appended, and that appendix does two separate jobs at once. Proline is the only proteinogenic amino acid whose side chain bonds back to its own backbone nitrogen, forming a ring that removes the amide hydrogen and locks rotation. Proteolytic enzymes generally need an extended, rotatable backbone at their active site, so bonds near proline are poor substrates for most of them — which is why proline-rich motifs recur throughout stabilised peptide design. The second job is subtractive: Pro-Gly-Pro occupies the positions where ACTH carries Arg-Trp-Gly, and those are the residues contributing to the parent hormone's adrenal-stimulating activity. One substitution therefore buys protease resistance and removes an unwanted pharmacology, which is unusually economical design.

Deep dive: the naming point worth getting right

Semax is near-universally described as an ACTH(4-10) analogue, and peer-reviewed paper titles use that phrase. Structurally it is not quite that. ACTH residues 4 to 10 are Met-Glu-His-Phe-Arg-Trp-Gly; Semax is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues match and the last three are wholly different — replacement rather than modification. PubChem, indexing by structure rather than design lineage, records it as ACTH(4-7) plus Pro-Gly-Pro. Neither name is wrong, but the loose one obscures the fact that the substituted segment is precisely the functionally consequential part.

Deep dive: reading an unevenly distributed evidence base

Semax's roughly 231 indexed records split along an unusual line. Mechanistic work — BDNF and trkB expression in rat hippocampus, transcriptomics in focal cerebral ischaemia, neurotrophin dynamics across brain regions — appears in international journals in English and can be assessed directly. Clinical work is concentrated in Russian-language publications, principally the Korsakov Journal of Neurology and Psychiatry, indexed by translated title and often without accessible English full text, much of it predating current standards for pre-registration and reporting. The honest position is that this is evidence which is difficult to verify independently, which is a different thing from evidence that is absent, and a different thing again from evidence that is established.

Research applications

▸Neurotrophin expression research (BDNF, NGF, TrkB, TrkA)
▸Neuroprotection and cerebral ischaemia models
▸Study of proline-stabilised peptide design
▸Comparative work on ACTH fragments without steroidogenic activity
▸Transcriptomic profiling in rodent brain models

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓Expect methionine oxidation as the degradation route (+16 Da; only one Met, so not +32)
✓No reducing agent needed — the sequence contains no cysteine
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles
✓Check whether a certificate reports net peptide content or gross salt weight

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Describing Semax as ACTH(4-10) without qualification

Fix: It shares only residues 4-7; Pro-Gly-Pro replaces Arg-Trp-Gly, and that replacement is the design's whole point.

✗ Treating Russian registration as equivalent to MHRA approval

Fix: Authorisations are jurisdictional and do not transfer. Semax has never been assessed by the MHRA, EMA or FDA.

✗ Reading a BDNF expression change as a demonstrated outcome

Fix: The studies measured gene and protein expression in rats. Expression is upstream of function and upstream again of any clinical claim.

✗ Assuming a named receptor exists

Fix: No primary receptor has been definitively established; the literature characterises downstream effects more confidently than the initiating event.

✗ Expecting ACTH-like adrenal effects

Fix: Semax does not stimulate adrenal steroidogenesis — the responsible residues were substituted out.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does Semax have a known receptor?: No primary receptor has been definitively established. The literature characterises downstream effects more clearly than the initiating interaction.
Were the BDNF studies done in humans?: No. The neurotrophin expression work is rodent, principally rat hippocampus and frontal cortex.
Does Semax raise cortisol like ACTH?: No. The Pro-Gly-Pro substitution removes the steroidogenic activity of the parent hormone.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Semax (ACTH Fragment Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum